<DOC>
	<DOCNO>NCT00167908</DOCNO>
	<brief_summary>The purpose study determine whether Amifostine provide additional protection salivary gland function achieve IMRT alone .</brief_summary>
	<brief_title>Study Amifostine IMRT Protecting Salivary Glands Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Pathologically confirm squamous cell cancer head neck Eligible site : oral cavity , oropharynx , hypopharynx , larynx . Patients require postoperative IMRT . KPS &gt; 70 % . Patient sign specific protocol consent prior registration . Calcium test within normal limit . No previous malignancy except nonmelanoma skin cancer cancer head neck control least 5 year . Labs complete 30 day registration ( CBC &amp; platelet , Ca++ , Alk phos , SGOT , Bili , albumin ) CXR CT simulation . Liver CT alk phos , SGOT , bili elevate . Bone scan elevate alk phos Metastatic disease . Patient use Salagen concurrent chemotherapy . Previous XRT head neck tumor . Active untreated infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>